PATENT APPLICATION 6-3-22

ADD OFFICE RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 3 0 2002

In the Application of:

Susheng GAN, et al.

Art Unit: 1645

TECH CENTER 1600/2900

Examiner: To be determined

Docket No.: 50229-287

Serial No.: 09/973,945

Filed: October 11, 2001

For: GENETIC INSULATOR FOR PREVENTING INFLUENCE BY ANOTHER GENE

**PROMOTER** 

## INFORMATION DISCLOSURE STATEMENT

Honorable Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

 $\boxtimes$ 

1.

In accordance with 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is directed to the cited references listed on the attached PTO-1449. No representation is made or intended that more relevant information does not exist or that the order of presentation of the information in any way reflects their relative pertinence. Applicants respectfully request that the cited information be expressly considered during the prosecution of this application and that the cited references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. If required, a copy of each reference is attached.

This Information Disclosure Statement is being filed within three months of the

U.S. filing date certification or f	OR before the mailing date of a first Office Action on the merits. Thus, no see is required.
the U.S. filing d	This Information Disclosure Statement is being filed more than three months after ate AND after the mailing date of the first Office Action on the merits, but ng date of a Final Rejection or Notice of Allowance.
Disclosure State foreign applicat	I hereby certify that each item of information contained in this Information ment was cited in a communication from a foreign patent office in a counter-part on not more than three months prior to the filing of this Information Disclosure C.F.R. 1.97(e)(1).
Statement was capplication or, to designated in 37	I hereby certify that no item of information in this Information Disclosure ited in a communication from a foreign patent office in a counterpart foreign my knowledge after making reasonable inquiry, was known to any individual C.F.R. §1.56(c) more than three months prior to the filing of this Information ment. 37 C.F.R. 1.97(e)(2).

c. Please charge the amount of \$240.00 in payment of the fee under 37 C.F.R. 1.17(p). Please credit or debit Deposit Account No. 13-0203 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached.
3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) petition(s) that the Information Disclosure Statement be considered. Please charge Deposit Account No. 13-0203 in the amount of \$130.00 for payment of the petition fee. Please credit or debit Deposit Account No. 13-0203 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached.
a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).
b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).
4. The reference(s) was/were cited in a counterpart foreign application. For the Examiner's information, attached is an English language version of the foreign search report. The foreign search report explains the relevance of any non-English language reference(s) cited on the attached PTO-1449.
Please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees associated with this communication to Deposit Account No. 50-0417.
Respectfully submitted,
MCDERMOTT, WILL & EMERY
Date: 5/29/2002 By: Lelle Allah
Kelli N. Watson Registration No. 47,170
600 13th Street, N.W. Washington, D.C. 20005-3096

KNW/dmd

Telephone: (202) 756-8000

				ÌÚ	כ
Modifi	ed Form 1449/PTO	Application Number	09/973,945		c
		Filing Date	October 11, 2001	- 33	4
	INFORMATION DISCLOSURE	First Named Inventor	Gan et al.	8	40
	STATEMENT BY APPLICANT	Group Art Unit	1645	200	7
1/2		Examiner Name	To be determined	8	7
삥	(use as many sheets as necessary)	Attorney Docket Number	050229-287		Π

Are - news

Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	•	Class	Sub Class	Filing Date If Appropriate
		6,100,448	Aug. 8, 2000	Thompson et al.		***		
		6,037,525	Mar. 14, 2000	Thompson et al.				
		6,040,185	Mar. 21, 2000	Dietrich et al.				
Prince of the second				FOREIGN PATENT DOCUMENT	rs»			
Exam Initials	Cite No.	Foreign Patent I		Name of Patentee(s) or Applicant(s)		Date of Publication		Translation Yes No
Initials	No.			on Effect in Mature Transgenic Plants ell. March 1994. Vol. 6, pages 417-42			1 Lysozyme	Matrix-
	<del></del>							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.